News
Renee Gala named next CEO of Jazz Pharmaceuticals: Gala will take over as president and CEO on August 11, 2025, following ...
TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.
Marcel Botha discusses ways the agency can ensure it gets the most accurate results possible from AI.
The new doll will include an insulin pump, a glucose monitor, and a dress featuring international symbols for diabetes ...
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
Life sciences marketing has long revolved around physicians. Traditionally seen as the gatekeepers of prescribing power, ...
Varda Space Industries announced its Series C fundraiser for medicine creation in space has reached $187 million. This now ...
ADRX-0405 is uniquely being tested during its 1a/b clinical trials. ADRX-0405 is labeled as a STEAP1 ADC (primarily ...
Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is ...
One of the major complaints levied against FDA by the current administration is that the approval process is too complicated, takes too long, and needs to be modernized. The new leadership pledged to ...
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Relapsed or Refractory Multiple Myeloma
Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...
In today’s fast-paced, innovation-fueled biopharma landscape, the traditional model of C-suite leadership is being turned on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results